Welcome to Helix Talk, a podcast presented by the Rosalm Franklin University College of Pharmacy.

This podcast is produced by pharmacy faculty to supplement study material and provide relevant drug and professional topics.

We're hoping that our real-life clinical pearls and discussions will help you stay up to date

and improve your pharmacy knowledge.

This is an educational production copyright Rosalind Franklin University of Medicine and Science.

This podcast contains general information for educational purposes only. This is not professional advice and should not be used in lieu of obtaining advice from a qualified health care provider.

And now, on to the show.

Welcome to Heelotts Talk, Episode 20. I'm your co-host, Dr. Kane.

I'm Dr. Patel.

And I'm Dr. Schumann.

And after a holiday break hiatus, we're back on with Helix Talk.

And today we're going to be talking about a landmark trial called the Smart Trial.

And the Smart Trial actually stands for Salmatorol, Multcenter asthma research trial, which was published in

chest in 2006.

So just to give a little bit of background with this one, this is a study. We knew some historical

data that seemed to imply that the L-ABAs or lab or lung-acting beta agonists, and what

these refer to either salmeterol or formoderol, this comes to medications that have been used for L-A-B-A-A-B-A-L-A-B-A-L-A-L-A-L-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-B-A-A-A-B-A-A-A-B-A-A-B-A-A-B-A-A-B-A-A-B-A-A-R-A-B-A-R-A-R-A-R-A So what they wanted to do with this trial is to determine whether or not salmeterol in particular

increased the respiratory or asthma related, either the life-threatening events or deaths.

So let me get this straight. This was not an efficacy trial, but it was actually a safety trial to see if this medication is causing adverse events.

Yeah, so I mean, why wouldn't you want to get enrolled in this study if you can go see if

this drug could cause you to have, you know, mortality?

I mean, that sounds reasonable.

...